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Abstract
Spinal bulbar muscular atrophy (SBMA) is one of a family of inherited neurodegenerative diseases caused by expansion of
CAG encoding polyglutamine repeats; in SBMA the affected gene is the androgen receptor. To understand further the
mechanisms that lead to neuronal cell death in SBMA, we generated SHSY5Y neuroblastoma cell lines that stably express
identical levels of wild-type (19 polyglutamine repeat) or SBMA (52 polyglutamine repeat) androgen receptor. Parental
SHSY5Y cells do not express detectable levels of the androgen receptor. In the absence of androgen, the transfected cell lines
have similar phenotypes and growth characteristics to parental SHSY5Y cells. However, upon treatment with androgen,
both cell lines undergo a marked dose-dependent loss of viability; this loss was significantly greater in cells expressing the
SBMA receptor. Morphological analyses of the androgen treated cells revealed that cell death bore hallmarks of apoptosis
involving altered nuclear morphology and cleavage of poly(ADP-ribose) polymerase and of caspase 3 in both wild-type and
SBMA cell lines. The caspase inhibitor VAD-fmk was able to decrease loss of viability of both cell lines on exposure to
androgen. ß 2001 Elsevier Science B.V. All rights reserved.
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1. Introduction
Spinal bulbar muscular atrophy (SBMA), also
known as Kennedy’s disease, is an adult onset genet-
ic form of motor neurone disease that is caused by
mutations in the androgen receptor gene [1]. The
mutations involve expansion of a polymorphic
CAG repeat that encodes a polyglutamine tract lo-
cated towards the amino terminus of the androgen
receptor. In the normal population, this polygluta-
mine tract varies between approx. 11 and 33 repeats
with a modal length of about 20 [2,3]; expansion of
the repeat to beyond approx. 40 causes disease [1].
SBMA is one of a group of inherited neurodegen-
erative diseases that are caused by expansion of
CAG encoding polyglutamine repeats and which in-
clude Huntington’s disease [4], dentatorubralpallido-
luysian atrophy (DRPLA) [5,6] and the spinocerebel-
lar ataxias [7^13]. The molecular mechanisms by
which expansion of polyglutamine tracts cause neu-
ronal cell death in these disorders are not understood
although favoured hypotheses are that the expansion
causes a gain of toxic function(s). Indeed, expanded
polyglutamine tracts have been shown to be toxic in
both cultured cells and transgenic mice [14^16].
A further complication to our understanding of
the mechanism of cell death in these polyglutamine
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disorders is that the normal function of most of the
polyglutamine containing proteins are not known.
However, this is not the case for SBMA; the andro-
gen receptor belongs to the nuclear receptor super-
family and mediates the e¡ects of androgens (see for
review [17]). In common with other members of this
family, the androgen receptor comprises a carboxy-
terminal ligand binding domain which binds andro-
gens, a conserved centrally located DNA binding
domain that interacts with androgen response ele-
ments in androgen-responsive genes, and an amino-
terminal transactivation domain. The polyglutamine
tract is located within the transactivation domain
and its expansion is now known to inhibit androgen
receptor function [18^20] and also to in£uence its
interactions with other transcription factors and ac-
tivators [21,22]. Decreased receptor function prob-
ably accounts for the partial androgen insensitivity
that is a further common phenotype of SBMA [23].
The mechanism(s) by which the SBMA receptor
causes motor neurone cell death is far from clear
(see Section 4). However, one suggestion is that poly-
glutamine expansion causes altered expression of
androgen receptor regulated genes and that this con-
tributes to SBMA [18^22,24,25]. As such, modulat-
ing androgen receptor function might be therapeutic
for SBMA although it is not clear whether treatment
with androgens or anti-androgens would be bene¢-
cial. In order to understand more fully how andro-
gens can in£uence neuronal cell survival, we created
SHSY5Y neuroblastoma cells that stably express
wild-type (19 polyglutamines) or SBMA (52 poly-
glutamines) androgen receptor. We ¢nd that andro-
gen stimulation of these cells induces a marked loss
of viability.
2. Materials and methods
2.1. Plasmids and SHSY5Y cell culture and
transfection
Expression vectors for human androgen receptors
harbouring 19 and 52 CAG repeats in pCMVneo
were as described [24]. SHSY5Y cells were routinely
cultured in DMEM/F12 mix containing 10% (v/v)
charcoal stripped foetal calf serum supplemented
with 2 mM glutamine, 100 IU ml31 penicillin and
100 Wg ml31 streptomycin (Life Technologies). For
transfection, cells were plated onto 100 mm diameter
dishes and transfected using a Profection CaPO4
transfection kit (Promega) according to the manufac-
turer’s instructions. Plasmids were linearised prior to
transfection with XbaI. 48 h post transfection, the
medium was replaced with selection medium (as
above, containing 600 Wg ml31 Genetecin (Life Tech-
nologies)), and colonies picked and expanded 2^3
weeks later [26]. Thereafter, cells were maintained
in medium containing 300 Wg ml31 Genetecin.
Testosterone was obtained from Sigma, the non-
metabolisable androgen R1881 from NEN DuPont
and staurosporine from Alexis.
2.2. Western blotting and indirect immuno£uorescence
The androgen receptor was detected using anti-
body N20 (Santa Cruz), poly(ADP-ribose) polymer-
ase (PARP) detected using antibody C-2-10 (Bio-
mol), and caspase 3 was detected using a rabbit
polyclonal antibody (Santa Cruz). Cells were har-
vested for SDS-PAGE by washing twice with ice-
cold phosphate bu¡ered saline (PBS) and then scrap-
ing into the appropriate bu¡er. For analyses of an-
drogen receptor expression and caspase 3 cleavage,
this was ice-cold 50 mM Tris-HCl pH 6.8 containing
1 mM EDTA, 0.6 mM PMSF, 0.5 mM bacitracin,
10 mM dithiothreitol and 10% (w/v) glycerol. There-
after, an equal volume of SDS-PAGE sample bu¡er
containing 4% SDS was added and the samples
heated in a boiling water bath. For detection of
PARP, samples were prepared according to the man-
ufacturer’s instructions for use of PARP antibody C-
2-10 (Biomol). All samples were separated on 10%
(w/v) acrylamide gels and transferred to Protran ni-
trocellulose membranes (Schleicher p Schuell) using
a Bio-Rad TransBlot system. Following blocking in
PBS containing 3% skimmed milk and 0.2% Tween
20, the blots were incubated with primary antibodies,
washed in PBS/0.2% Tween 20, incubated with
horseradish peroxidase conjugated anti-mouse or
anti-rabbit immunoglobulins (Igs) (Amersham) and
following further washes developed using an en-
hanced chemiluminescence system (Amersham) ac-
cording to the manufacturer’s instructions.
To compare androgen receptor expression levels in
the di¡erent transfected cell clones, quantitative
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Western blots were performed following methods
similar to those previously described by us [27].
Brie£y, 5U106 cells from each population were pro-
cessed identically for SDS-PAGE and equal volumes
of these samples then loaded on SDS-PAGE gels and
probed for the androgen receptor by Western blot-
ting as described above. To con¢rm that equal
amounts of protein were loaded, identically loaded
gels were Coomassie stained and three selected bands
from each sample quanti¢ed by densitometric analy-
ses using a Bio-Rad GS-710 Imaging Densitometer
equipped with Quantity One software. The signals
from these scans were then compared with the signals
obtained from the androgen receptor Western blots.
For immunocytochemical and nuclear morphology
studies, cells were ¢xed in 4% (w/v) paraformalde-
hyde in PBS for 20 min, permeabilised in 0.1%
(w/v) Triton X-100 in PBS for 10 min and then pro-
cessed for immuno£uorescence. Following blocking
with 5% (v/v) foetal bovine serum/0.2% (w/v) Tween
20 in PBS for 1 h, cells were probed with primary
antibody N20 to the androgen receptor diluted in
blocking solution. Antibodies were detected using
goat anti-rabbit Igs coupled to Oregon Green or
Texas red (Molecular Probes). Nuclear morphology
was analysed by labelling with Hoechst 33342 stain.
Cells were mounted in Vectashield (Vector Labs).
2.3. Cell viability assays
Cell viability was assayed using a commercial (3-
(4,5-dimethylthiazol-2-yl)-5-(carboxymethoxyphenyl)-
2-(4-sulphophenyl)-2H-tetrazolium, inner salt (MTS))
assay according to the manufacturer’s instructions
(CellTiter 96, Promega). Lactate dehydrogenase
(LDH) assays were also performed using a commer-
cial kit (CytoTox 96, Promega).
3. Results
We utilised SHSY5Y cells since pilot studies re-
vealed that these human neuroblastoma cells do
not express detectable levels of androgen receptor
(see also Figs. 1a and 2d). Studies on the e¡ect of
expressing wild-type or SBMA mutant androgen re-
ceptor by transfection in these cells would not there-
fore be complicated by co-expression of the endoge-
nous receptor.
We generated several di¡erent transfected
SHSY5Y cell clones and screened these by quantita-
tive Western blotting to identify ones that expressed
similar levels of wild-type and SBMA receptors.
These studies identi¢ed two clones that expressed
levels of wild-type and SBMA receptors that were
indistinguishable (clones C28 and K6 respectively)
(Fig. 1). These two clones were therefore selected
for further investigations.
Both C28 and K6 cells had morphologies that
were similar to parental non-transfected cells and
grew in androgen free medium in a fashion that
was not noticeably di¡erent to parental SHSY5Y
cells (Fig. 2a^c). Treatment of C28 and K6 cells
with 1 nM R1881 for 2 h induced nuclear transloca-
tion of the androgen receptor (Fig. 2d^i) but no evi-
dence of cytoplasmic or nuclear aggregates was ob-
served in any of the cells either prior to, or after
androgen treatment. Similarly, we did not detect in-
clusions in any of the other cell lines expressing wild-
type or SBMA receptor that were examined.
Upon treatment with R1881 for longer periods,
both of the transfected cell lines displayed a marked
time- and dose-dependent loss in cell viability as de-
Fig. 1. Androgen receptor expression in non-transfected paren-
tal SHSY5Y cells and SHSY5Y cells stably expressing either a
wild-type androgen receptor (C19 and C28 cells) or an SBMA
mutant androgen receptor (K6 and K20 cells). (a) Western blot
to detect the androgen receptor; (b) full length identically
loaded Coomassie stained gel to demonstrate equal protein
loadings. Molecular masses in kDa are indicated on the left in
panel b.
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termined by MTS assays; non-transfected parental
cells were una¡ected by androgen (Fig. 3). Similar
results were obtained using LDH assays (data not
shown). This loss in viability was signi¢cantly greater
in clone K6 expressing the SBMA mutant androgen
receptor than in clone C28 expressing the wild-type
receptor. Similar results were obtained with testoster-
one treatment.
Analyses of two further clones that expressed the
androgen receptor at di¡erent levels (C19 expressing
the wild-type receptor and K20 expressing the
SBMA receptor (Fig. 1)) revealed that they too ex-
hibited a loss of viability following androgen treat-
ment. Following a 5 day treatment with 1 nM
R1881, C19 cells displayed 20% and K20 cells 65%
survival (relative to non-transfected SHSY5Y cells)
as determined by MTS assays. Under the same ex-
perimental conditions, C28 and K6 cells displayed
50% and 20% survival respectively (Fig. 3). Quanti-
tative Western blots (see Fig. 1) revealed that C19
cells expressed 1.8 times and K20 cells 0.23 times the
level of receptor as C28 and K6 cells. Thus, several
SHSY5Y cell lines expressing di¡ering levels of the
androgen receptor display a loss of viability in re-
sponse to androgen treatment and this loss is at least
partially related to the expression level of the recep-
Fig. 2. Morphology and immunocytochemical analyses of parental SHSY5Y cells and SHSY5Y cells stably expressing either a wild-
type androgen receptor (C28 cells) or an SBMA mutant androgen receptor (K6 cells). (a^c) Phase contrast images of SHSY5Y, C28,
and K6 cells respectively. (d^f) SHSY5Y, C28, and K6 cells stained with androgen receptor antibody N20 following treatment with
1 nM R1881 for 2 h to demonstrate nuclear localisation; (g^i) the same ¢elds stained with Hoechst 33342 to show nuclei. (j^l)
SHSY5Y, C28, and K6 cells stained with Hoechst 33342 following 10 pM R1881 treatment for 3 days; pyknotic and fragmenting nu-
clei typical of apoptotic cells are arrowed in the K6 cells. Scale bars: 50 Wm.
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tor. These studies also provide further evidence that
cells expressing the SBMA receptor are more sensi-
tive to androgen than cells expressing the wild-type
receptor although this relationship is not linear (C19
cells are equally susceptible to androgen as K6 cells
despite expressing 1.8 times the level of receptor and
K20 cells are only moderately less sensitive to andro-
gen than C28 cells despite expressing only 0.23 times
their level).
The mechanism(s) that lead to neuronal cell loss in
SBMA or indeed in any of the polyglutamine repeat
diseases are not known. However, apoptosis is one
proposed method of cell death for these disorders
(see for example [15,28,29]). Since altered nuclear
morphology is a marker for apoptosis, we analysed
nuclear shape in the androgen treated cells by stain-
ing with Hoechst 33342. For these studies, we fo-
cused on cells exposed to 10 pM R1881 for 3 days
since this particular treatment produced the most
marked di¡erences in survival between the cell types
as determined by the MTS assays (see Fig. 3). Nuclei
were scored for apoptotic changes (pyknotic/frag-
menting nuclei) and these studies revealed that
R1881 treatment resulted in 3.6% abnormal nuclei
in C28 cells (n = 443) and 35.5% abnormal nuclei
Fig. 3. MTS cell viability assays of SHSY5Y cells and SHSY5Y
cells expressing either a wild-type androgen receptor (C28 cells)
or an SBMA mutant androgen receptor (K6 cells). Cell viability
is expressed relative to untreated cells in each case. Cells were
either untreated or treated with 10 pM (10311 M) or 1 nM
(1039 M) R1881 for 3 days (a) or 5 days (b). Error bars are
S.E.M.
Fig. 4. Androgen stimulation causes cleavage of proteins associ-
ated with apoptosis in SHSY5Y cells expressing either a wild-
type androgen receptor (C28 cells) or an SBMA mutant andro-
gen receptor (K6 cells). (a) PARP cleavage in cells that were
untreated (UN) or treated with 0.1 nM R1881 for either 3 or 5
days (3d, 5d). As a positive control, parental SHSY5Y cells
(SHSY5Y) were also treated with 10 WM staurosporine (STAU)
for 2 h to induce apoptosis. The 116 and 85 kDa PARP species
are indicated. (b) Caspase 3 cleavage in C28 and K6 cells, but
not parental SHSY5Y cells exposed to 1 nM R1881 for 5 days.
Cleaved (17 kDa) and uncleaved (32 kDa) caspase 3 bands are
identi¢ed. (c) The caspase inhibitor VAD-fmk increases viability
of cells exposed to 1 nM R1881 for 5 days. Cells were treated
with 1 nM R1881 in the presence and absence of VAD-fmk.
Cell viabilities were determined by MTS assays and are ex-
pressed relative to cells without VAD-fmk in each case.
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induced in K6 cells (n = 327) as compared to parental
SHSY5Y cells (see Fig. 2j^l for representative im-
ages). These ¢gures are similar to those obtained
by the MTS assays (cf. Fig. 3) which show 7.5%
and 45% losses of viability in C28 and K6 cells re-
spectively.
Proteolytic cleavage of PARP to generate an 85
kDa fragment is a further marker for apoptosis
[30,31]. We therefore analysed PARP cleavage by
Western blotting in the SHSY5Y, C28 and K6 cells
following treatment with 1 nM R1881 for 3 and 5
days. Following R1881 treatment, the 85 kDa
cleaved product was clearly discernible in both K6
and C28 cells with the level being lower in C28 cells
(Fig. 4a).
To further investigate the possibility that death in
response to androgen stimulation was by apoptosis
we utilised an antibody against caspase 3. On activa-
tion, caspase 3 is cleaved to generate a faster migrat-
ing species on a Western blot. After stimulation with
1 nM R1881 for 5 days both cell lines showed
cleaved caspase 3, whereas parental cells did not
(Fig. 4b). We also used the caspase inhibitor VAD-
fmk to inhibit cell death in cells exposed to 1 nM
R1881 (Fig. 4c). This increased survival of both cell
lines; K6 and C28 viability was increased by 68%
and 33% respectively. The small increase in viability
seen in parental cells (11%) is probably due to inhi-
bition of naturally occurring apoptosis in the cells.
4. Discussion
A number of other groups have now studied the
e¡ects of wild-type and SBMA androgen receptor
expression on cell survival in transfected cells
[29,32^37]. The results of these studies are variable.
Some groups have reported little if any e¡ect on
viability of either the wild-type or SBMA receptor
[32,33] whereas other reports demonstrate toxicity
of both wild-type and SBMA receptors with SBMA
receptors exhibiting increased toxicity [29,35]. How-
ever, in one of these studies, androgens have little
e¡ect on the toxicity [35] whereas in the other study,
androgen treatment rescues cells from toxicity [29]. A
further study suggests that toxicity requires proteo-
lytic cleavage of the receptor and formation of ag-
gregates containing the polyglutamine tract [34]. It
has also been shown that formation of aggregates
requires androgens [37,38]. Most recently, it has
been suggested that androgen stimulation promotes
aggregate formation but may also be neuroprotective
[37]. These di¡erent results probably re£ect the dif-
ferent cell types used for investigation, the di¡erent
levels of expression of the androgen receptor in the
cells including whether the cells express endogenous
receptor, and ¢nally whether stable or transient
transfection methods were used.
In the studies reported here, we have stably ex-
pressed wild-type (19 polyglutamine repeats) and
SBMA (52 polyglutamine repeats) androgen recep-
tors in SHSY5Y cells. These are a human neuronal
cell type that have been extensively used to study
mechanisms of cell death in neurodegenerative dis-
eases (see for example [39,40]). We selected for study
two clones that express identical levels of wild-type
and SBMA receptors (clones C28 and K6 respec-
tively). Since parental SHSY5Y cells do not express
the androgen receptor, we were therefore able to
compare directly how polyglutamine repeat length
in£uenced cell viability in the absence of an endoge-
nous receptor. This is an important feature of our
experimental approach since only one copy of the
androgen receptor gene is expressed per cell in vivo
in humans (the androgen receptor is located on the
X-chromosome and so one copy is silenced in fe-
males due to X-inactivation). The transfected
SHSY5Y cells we have generated therefore model
in vivo androgen receptor expression more closely
than in some earlier studies.
In the absence of androgen, C28 and K6 cells have
similar morphologies and growth rates to parental
SHSY5Y cells. However, upon treatment with an-
drogens, C28 and K6 cells both undergo a dose-de-
pendent loss of viability; no such loss is seen in the
parental cells. Furthermore, analyses of several other
SHSY5Y cell clones stably transfected with either
wild-type or SBMA androgen receptor but express-
ing di¡ering levels of the receptors also revealed
losses of viability following androgen treatment
(data not shown). Alterations to expression of andro-
gen-responsive gene(s) is thus toxic to SHSY5Y cells.
The identi¢cation of the gene(s) that mediate this
toxicity is therefore an important avenue for future
investigation.
Interestingly, although androgens induced a loss of
BBADIS 62020 24-4-01
A.J. Grierson et al. / Biochimica et Biophysica Acta 1536 (2001) 13^2018
viability in both C28 and K6 cells, stimulation of the
SBMA receptor induced a signi¢cantly higher rate of
cell death. Studies of two further clones expressing
wild-type and SBMA receptors (C19 and K20) pro-
vided further support for this notion. Stimulation of
the SBMA receptor is therefore more toxic than
stimulation of the wild-type receptor in SHSY5Y
cells. This may be because the wild-type and
SBMA receptors induce expression of di¡erent
gene(s) following androgen stimulation which then
leads to cell death, or that they induce expression
of androgen-responsive genes to di¡ering levels
which again induces a toxic e¡ect. Alternatively,
the SBMA receptor may cause cell death in a manner
that is unrelated to expression of androgen-respon-
sive genes but that is dependent upon androgen stim-
ulation. Indeed, the mechanism(s) of cell death in
SBMA and all of the polyglutamine repeat diseases
are far from clear. One suggestion is that polygluta-
mine tract expansion induces the formation of ag-
gregates that are toxic to neurones [24,34,38]. How-
ever, we were unable to detect androgen receptor
aggregates in the transfected cells studied here (either
before or after androgen treatment) although we can-
not exclude the possibility that submicroscopic ag-
gregates are present in the cells. Recent data have
suggested that polyglutamine containing aggregates
may not be toxic to cells [28,41,42] and this includes
aggregates containing the SBMA receptor [37].
A further proposed toxic mechanism involves acti-
vation of apoptotic pathways since expression of
SBMA receptors has been shown to induce morpho-
logical changes that are characteristic of apoptosis
[29,35]. Our ¢ndings are in agreement with these
studies since we too observe altered nuclear morphol-
ogy consistent with apoptosis in the androgen treated
K6 cells. In addition, we also detected proteolytic
cleavage of PARP, a biochemical marker for apopto-
sis [30,31] upon androgen stimulation and this cleav-
age was more prominent in K6 cells. PARP is
cleaved by caspases (caspase 3 and 7) as part of
the apoptotic process (for reviews see [43,44]). We
also detected cleavage of caspase 3 upon androgen
stimulation of our stable cells, suggesting that this
caspase is involved in the cell death induced by an-
drogen treatment. Interestingly the androgen recep-
tor has been shown to undergo proteolysis by mem-
bers of the caspase family of proteases, including
caspase 3 [29,45]. It has also been suggested that
cleavage of the SBMA androgen receptor may medi-
ate its toxicity [24,29]. We were able to detect a faster
migrating species with the N20 androgen receptor
antibody; however, we did not detect any increase
in this band upon androgen treatment, or observe
any de novo cleavage products after 5 days of 1 nM
R1881 (data not shown). Since we had used several
criteria to demonstrate apoptosis in these cells,
we chose to try and prevent cell death using a well
characterised caspase inhibitor. Treatment with
VAD-fmk was able to increase cellular survival in
both cell lines after 5 days of 1 nM R1881. The
results presented here therefore suggest that andro-
gen induced death of SHSY5Y cells expressing the
SBMA androgen receptor may well involve apoptotic
mechanisms.
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